Skip to main content
Clinical Trials/NCT07467798
NCT07467798
Not yet recruiting
Not Applicable

A Proof-of-concept Study of Ultrasound Stimulation of the Neck to Enhance Anti-shock Efficacy

Tao Liu0 sites30 target enrollmentStarted: May 1, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Tao Liu
Enrollment
30
Primary Endpoint
The proportion of patients whose SBP exceeded 90 mmHg and remained stable for at least 5 minutes within 5 minutes of receiving LIPUS treatment or control group treatment

Overview

Brief Summary

The objective of this clinical study is to evaluate the initial efficacy and safety of LIPUS as an adjunct to standard therapy in patients with shock. The investigators will invite patients to participate in a proof-of-concept study investigating the efficacy of neck ultrasound stimulation to enhance anti-shock treatment, involving brief exposure to low-intensity pulsed ultrasound. This study examines whether LIPUS can enhance blood pressure in patients with shock, improve the efficacy of antihypotensive treatment, and reduce the dosage and duration of vasoactive drugs during active pharmacological therapy. By applying LIPUS as an adjunct to conventional treatment in clinical cases of shock, we aim to determine the clinical value of LIPUS and establish a theoretical foundation for developing innovative new therapies for shock.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with shock who are ≥18 years of age and have a systolic blood pressure (SBP) between 60 mmHg and 90 mmHg;
  • Patients with arterial blood pressure monitoring or peripheral arterial pressure monitoring with intervals of single-digit minutes;
  • Patients with mild to moderate shock with a shock index (SI) of 1 ≤ SI ≤ 2;
  • Patients with complete medical records.

Exclusion Criteria

  • Patients with unstable condition and estimated survival time \<24 hours;
  • Patients requiring emergency surgery to achieve control of their condition;
  • Perioperative patients requiring surgery due to conditions other than hypotension;
  • Pregnant or lactating patients;
  • Patients with neck wounds and/or carotid artery plaques who are unsuitable for ultrasound stimulation of the left carotid sinus;
  • Patients deemed unsuitable for inclusion by the investigator.

Arms & Interventions

Experimental group

Experimental

Intervention: Low-intensity pulsed ultrasound (Device)

Control group

No Intervention

Outcomes

Primary Outcomes

The proportion of patients whose SBP exceeded 90 mmHg and remained stable for at least 5 minutes within 5 minutes of receiving LIPUS treatment or control group treatment

Time Frame: From the start of treatment to 60 minutes after the intervention

The proportion of patients with SBP exceeding 90 mmHg and remaining stable for at least 5 minutes following ultrasound therapy

Time Frame: From the start of treatment to 60 minutes after the intervention

Secondary Outcomes

  • The proportion of cases where blood pressure increased by more than 10,15,or 20 mmHg above pre-treatment levels and remained elevated for at least 5 minutes, along with the duration of elevation.(From the start of treatment to 60 minutes after the intervention)
  • Total hospitalization costs(3 months)
  • The total duration from achieving a blood pressure of ≥90 mmHg after treatment until it stabilizes and subsequently drops back to ≤90 mmHg.(From the start of treatment to 60 minutes after the intervention)
  • Time from initiation of LIPUS therapy to patient's SBP exceeding 90 mmHg(From the start of treatment to 60 minutes after the intervention)
  • Shock Index (SI) Changes(Before treatment and 60 minutes after treatment)
  • Heart Rate Variability (HRV) Changes(Before treatment and 60 minutes after treatment)
  • Drug dosages from the initiation of LIPUS therapy until the patient's SBP reaches the effective target(From the start of treatment to 60 minutes after the intervention)
  • mRS scores for patients in the follow-up control group and experimental group(3 months)
  • Length of Stay in Intensive Care Unit (ICU)(3 months)

Investigators

Sponsor
Tao Liu
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Tao Liu

investigator

The George Institute

Similar Trials